|
Title
|
Published
|
Price
|
|
Commercial Insight: Asthma & COPD - On the verge of generic entry
By: Datamonitor
Introduction Although the respiratory market has expanded considerably from 2004 to 2008, growth in the seven major markets is slowing down from 2009 to 2011, after which sales will decline due to patent expiries of leading
|
more...
|
6/10/2009
|
$15,200.00
|
|
Asthma and COPD Market Forecast
By: Datamonitor
Introduction Although the respiratory market has expanded considerably from 2004 to 2008, growth in the seven major markets is slowing down from 2009 to 2011, after which sales will decline due to patent expiries of leading
|
more...
|
6/10/2009
|
$15,200.00
|
|
Chinese Markets for Asthma Treatment Drugs
By: Asia Market Information & Development Company
China's demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic
|
more...
Search inside this report
|
6/1/2009
|
$4,000.00
|
|
China Asthma Drug Market Report
By: Draco Healthcare Consulting LLC
According to the 2004 Global Burden of Asthma Report, there were about 300 million asthma patients worldwide. One out of every 250 disease-related deaths was caused by asthma. In China, the incidence rate of asthma
|
more...
|
5/1/2009
|
$4,500.00
|
|
The 2009 Report on Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations: World Market Segmentation by City
By: Icon Group International, Inc.
This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a “borderless world”, cities become a more important criteria in prioritizing markets,
|
more...
Search inside this report
|
5/1/2009
|
$795.00
|
|
Asthma Therapy Area Pipeline Report
By: Life Science Analytics (LSA)
Life Science Analytics', Asthma Therapy Area Pipeline Report contains detailed information on the asthma drug pipeline. This report provides insight into the pipeline status of asthma drugs by company and by stage as well as
|
more...
Search inside this report
|
3/16/2009
|
$1,495.00
|
|
Asthma - Evaluation and Management
By: Apollo Managed Care Consultants
Diagnosis, non-pharmaceutical and pharmaceutical management to improve the quality of care while reducing ER and hospital care. Authoritative references. Resources include disability evaluation/certification for asthma, patient education handouts, web
|
more...
|
3/6/2009
|
$55.00
|
|
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs 2008
By: Espicom Healthcare Intelligence
Providing…
Product forecasts by value 2007/2013 for 20 leading therapies
Patent expiry opportunities to 2018
Inhalable and nasal spray generics in market context
A review of pipeline developments which will affect the sector going forward
|
more...
Search inside this report
|
10/15/2008
|
$1,890.00
|
|
Forecast Insight: Asthma/COPD - Little long-term future for long-acting single-agent inhalers?
By: Datamonitor
Introduction
The respiratory market will continue to grow with the same rate over the next few years, with a slight dip between 2012 and 2015 due to the patent expiries of leading products. Growth
|
more...
|
8/7/2008
|
$15,200.00
|
|
Stakeholder Insight: Asthma - Over-prescribing is common in intermittent and mild forms of asthma
By: Datamonitor
Introduction Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow limitation and controller medications to target underlying inflammation. Datamonitor's research shows that almost all patients (even those with mild intermittent asthma)
|
more...
|
7/1/2008
|
$15,200.00
|
|
Stakeholder Insight: Asthma
By: Datamonitor
Introduction
Asthma is managed using a step-wise approach, with bronchodilators to relieve symptoms of airflow limitation and controller medications to target underlying inflammation. Datamonitor’s research shows that almost all patients (even those with mild intermittent
|
more...
|
6/25/2008
|
$15,200.00
|
|
Asthma
By: Decision Resources
An inhaled drug with a novel mechanism of action for the treatment of persistent asthma.
Using Target Product Profiles in Your Market Strategy
Our Target Product Profiles qualitatively predict the market
|
more...
|
3/30/2008
|
$5,625.00
|
|
U.S. Asthma/COPD Market
By: Frost & Sullivan
This Frost & Sullivan research service titled U.S. Asthma/COPD Market provides an overview of the medication used to treat asthma and COPD and provides forecasts for the patient population and market revenues, along with a
|
more...
|
10/23/2007
|
$6,000.00
|
|
European Asthma Therapeutics Markets
By: Frost & Sullivan
Research Overview
This Frost & Sullivan research service titled European Asthma Therapeutics Markets provides key challenges, forecasts and recommendations for the asthma therapeutics market. In this research, Frost
|
more...
|
7/30/2007
|
$7,000.00
|
|
Commercial Insight: Asthma & Copd - Combination Products Still Have Blockbuster Potential
By: Datamonitor
Introduction Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product
|
more...
|
7/11/2007
|
$15,200.00
|
|
U.S. COPD Market - Therapeutic Overview and Patient Outlook
By: Frost & Sullivan
The Frost & Sullivan research service titled U.S. COPD Market: Therapeutic Overview and Patient Outlook provides insight into marketed products, patient forecasts, and selected therapeutic approaches that are outside of current marketed areas. In this
|
more...
|
6/18/2007
|
$6,000.00
|
|
Disease and Therapy Review: Chronic Obstructive Pulmonary Disease
By: Timely Data Resources, Inc.
The Chronic Obsturctive Pulmonary Disease (COPD) Disease and Therapy Review provides prevalence numbers and percentages for major countries worldwide. Information on diagnosis and treatment are provided, as well as treatment and dosing costs of
|
more...
Search inside this report
|
5/1/2007
|
$995.00
|
|
Conference Documentation: Asthma & COPD
By: SMI Publishing, Ltd
Kim Kuebler, Medical Scientist, Boehringer-Ingelheim
It is estimated that the global annual sales in the asthma and COPD market are due to increase by over $10 billion US dollars within the next 5 years and
|
more...
|
4/25/2007
|
$998.00
|
|
Stakeholder Opinions: Asthma Phenotypes A changing paradigm
By: Datamonitor
Introduction
An estimated 34 million people are diagnosed with asthma in the major markets. The disease can be broken down into various phenotypes, differentiated by severity, trigger, or predominant inflammatory type. These phenotypes may
|
more...
|
3/26/2007
|
$3,800.00
|
|
Disease and Therapy Review: Asthma
By: Timely Data Resources, Inc.
The Asthma Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, an overview of short-acting medications for quick relief of symptoms, and a review of treatments used to provide
|
more...
Search inside this report
|
1/1/2007
|
$995.00
|
|
Pipeline Insight: Asthma/COPD - Targeted Therapies On The Horizon
By: Datamonitor
Introduction
The total asthma and COPD population in 2006 is estimated to be 44.8 million and 28.8 million respectively. While the majority of patients are well controlled with current therapies, the remaining unmet needs are
|
more...
|
11/7/2006
|
$11,400.00
|
|
Asthma Therapeutics
By: Global Industry Analysts
This report analyzes the worldwide markets for Asthma Therapeutics in US$ Million. The major therapeutic segments analyzed are Inhaled corticosteroids, Short acting beta agonists, Long acting beta agonists, Combinations, and Anti- leukotrienes. The report provides
|
more...
|
10/1/2006
|
$3,950.00
|
|
The World Market for Prescription Respiratory Drugs
By: Kalorama Information
The global market for prescription respiratory drugs encompasses a wide variety of products that treat both common everyday respiratory illnesses as well as serious chronic conditions such as COPD. Technological developments and improved delivery methods
|
more...
Buy by the section | Search inside this report
|
10/1/2006
|
$3,500.00
|
|
The 2007-2012 Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations in the United States
By: Icon Group International, Inc.
This study covers the latent demand outlook for bronchial dilator and anti-asthmatic pharmaceutical preparations across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.)
|
more...
|
9/28/2006
|
$495.00
|
|
Asthma and COPD Drug Discoveries: What The Future Holds
By: Espicom Healthcare Intelligence
A fast growing sector with strong products and players - but what will the COPD/Asthma landscape look like 5 years from now?
The global asthma and COPD market is currently worth around US$20 billion.
|
more...
Search inside this report
|
8/17/2006
|
$2,460.00
|
|
Title
|
Published
|
Price
|
(0 items)
